On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster

Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.  

Waiting
• Source: Shutterstock

It’s a nail-biting time for UK-based biotech Verona Pharma plc. Over 15 years since its founding, Verona will soon deliver results of a second Phase III trial of chronic obstructive pulmonary disease (COPD) hopeful ensifentrine. If it replicates the strongly positive efficacy and safety data seen in a first study, the company has a blockbuster in its hands, according to analysts. If not, Verona's survival may be at stake.

This binary outlook is typical for an asset-focused biotech. What’s less ordinary about Nasdaq-listed Verona is that it’s gearing up...

More from Global Vision

More from In Vivo